Page 60 - Genentech News Today

Investigators will evaluate prophylactic tocilizumab prior to treatment with teclistamab.

On November 17, 2023, Genentech, Inc., Hoffmann-La Roche Inc., and Biogen Inc. ("Plaintiffs") filed a BPCIA complaint ("Complaint") against Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories SA ("DRL SA")...

– If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposure – – Interim analysis results from first-of-its-kind Phase III...

Healthcare professionals greatly value navify Tumor Board for improving tumour board meeting experiences, offering a holistic view of data, facilitating multidisciplinary team collaboration and...

Its positioning in biotech will likely take a long while to pay off.

If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposureInterim analysis results from first-of-its-kind phase III OUtMATCH study...

Retrospective, real-world results showed that patients treated with oral decitabine and cedazuridine and standard parenteral hypomethylating agents (HMAs) for myelodysplastic syndrome (MDS) demonstrated similar levels of comorbidities and disease burden to patients treated with intravenous (IV)/subcutaneous (SC) HMAs.

DENVER--(BUSINESS WIRE)--Dec 19, 2023--

Its positioning in biotech will likely take a long while to pay off.

Healthpeak Properties, Inc. , a leading owner, operator, and developer of real estate for healthcare discovery and delivery, today announced it has received approval of entitlements for Phases II...